TLDR Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
The document discussed guidelines for the primary care management of male lower urinary tract symptoms (LUTS), highlighting the potential benefits of dual therapy with a 5α-reductase inhibitor and an alpha-adrenergic blocker to reduce the risk of side effects from benign prostatic hyperplasia (BPH), such as urinary retention. It also mentioned a randomized placebo-controlled study on the use of finasteride for chronic nonbacterial prostatitis, emphasizing the need for cautious evaluation of treatments due to the lack of comparative trials. Additionally, the document noted ongoing interest in the epidemiology and severity grading of LUTS symptoms like frequency and nocturia.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
1054 citations
,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
17 citations
,
November 1997 in “Andrology” Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
2 citations
,
January 2023 in “Uro” UHP-sCESr is as effective as HESr for treating BPH symptoms.
50 citations
,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
98 citations
,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.